Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Adoptive immunotherapy using genetically modified T-cells with a chimeric antigen receptor (CAR) is a promising modality for cancer treatment, because the CAR-grafted T-cells can directly recognize and kill tumor cells, expressing a specific tumor-associated antigen (TAA), in a human leukocyte antigen (HLA)-independent manner. Optimal molecular designs of the CAR and a careful choice of the target TAA are requisite to attain a significant response in CAR-mediated therapy. This review provides a brief overview of the past studies and the present state of CAR research, especially focusing on the development of the CAR protein architecture.
Department of Biochemistry, Faculty of Medicine, Fukuoka University, 7-45-1 Jonan-ku, Fukuoka 814-0180, Japan. shirasu@fukuoka-u.ac.jp
Naoto
N
Shirasu
Masahide
M
Kuroki
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000637:transplantation*
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins